Patents by Inventor Jotham Wadsworth Coe

Jotham Wadsworth Coe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6462035
    Abstract: The present invention relates to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R1, R2, R3 and Z are as defined herein, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: October 8, 2002
    Assignee: Pfizer Inc.
    Inventor: Jotham Wadsworth Coe
  • Publication number: 20020132824
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: April 23, 2002
    Publication date: September 19, 2002
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Publication number: 20020111350
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: April 22, 2002
    Publication date: August 15, 2002
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Publication number: 20020086871
    Abstract: The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant &agr;7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant &agr;7 nicotinic receptor agonist.
    Type: Application
    Filed: October 23, 2001
    Publication date: July 4, 2002
    Inventors: Brian Thomas O'Neill, Jotham Wadsworth Coe, Christopher John O'Donnell
  • Patent number: 6410550
    Abstract: Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: June 25, 2002
    Assignee: Pfizer INC
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Publication number: 20020072525
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: February 13, 2002
    Publication date: June 13, 2002
    Inventors: Jotham Wadsworth Coe, Paige Roanne Palmer Brooks
  • Publication number: 20020016334
    Abstract: Pharmaceutical compositions are disclosed for the treatment of attention deficit hyperactivity disorder (ADHD). The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-ADHD agent and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: May 25, 2001
    Publication date: February 7, 2002
    Inventors: Jotham Wadsworth Coe, Steven Bradley Sands, Edmund Patrick Harrigan, Brian Thomas O'Neill, Eric Jacob Watsky
  • Publication number: 20020010192
    Abstract: Pharmaceutical compositions are disclosed for the treatment of obesity, an overweight condition and compulsive overeating. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an anti-obesity agent or weight loss facilitator or promoter and a pharmaceutically acceptable carrier. The method of using these compounds is also disclosed.
    Type: Application
    Filed: May 7, 2001
    Publication date: January 24, 2002
    Inventors: Jotham Wadsworth Coe, Steven Bradley Sands, Edmund Patrick Harrigan, Brian Thomas O'Neill, Eric Jacob Watsky
  • Publication number: 20010036949
    Abstract: A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal comprising administration of a nicotine receptor partial agonist or a pharmaceutically acceptable salt thereof; and an acetylcholinesterase inhibitor, butylcholinesterase inhibitor, an estrogenic agent, selective estrogen receptor modulator or muscarinic agonist or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The nicotine receptor partial agonist and acetylcholinesterase inhibitor, butylcholinesterase inhibitor, estrogen, selective estrogen receptor modulator or muscarinic agonist are present in amounts that render the composition effective enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease, mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease dementia, Huntington's Disease, Stroke, TBI, AIDS associated dementia and schizophrenia.
    Type: Application
    Filed: January 16, 2001
    Publication date: November 1, 2001
    Inventors: Jotham Wadsworth Coe, Steven Bradley Sands, Edmund Patrick Harrigan, Brian Thomas O'Neill, Eric Jacob Watsky
  • Patent number: 6130217
    Abstract: This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: October 10, 2000
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Jotham Wadsworth Coe, Takushi Kaneko, Mikel Paul Moyer